tiprankstipranks
RedHill Biopharma (RDHL)
NASDAQ:RDHL

RedHill Biopharma (RDHL) Stock Price & Analysis

730 Followers

RDHL Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.26 - $6.81
Previous Close$0.53
Volume428.59K
Average Volume (3M)1.78M
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$15.00K
Total Debt (Recent Filing)$7.47M
Price to Earnings (P/E)-0.2
Beta2.41
May 07, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-3.16
Shares Outstanding29,703,027
10 Day Avg. Volume1,042,890
30 Day Avg. Volume1,784,969
Standard Deviation0.53
R-Squared0.12
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-0.13
Price to Sales (P/S)0.25
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

43.33%<0.01%0.36%56.31%
43.33%
Insiders
0.36% Other Institutional Investors
56.31% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

RDHL FAQ

What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $0.26 and its highest was $6.81 in the past 12 months.
    What is RedHill Biopharma’s market cap?
    Currently, no data Available
    When is RedHill Biopharma’s upcoming earnings report date?
    RedHill Biopharma’s upcoming earnings report date is May 07, 2024 which is in 41 days.
      How were RedHill Biopharma’s earnings last quarter?
      Currently, no data Available
      Is RedHill Biopharma overvalued?
      According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does RedHill Biopharma pay dividends?
        RedHill Biopharma does not currently pay dividends.
        What is RedHill Biopharma’s EPS estimate?
        RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does RedHill Biopharma have?
        RedHill Biopharma has 29,703,028 shares outstanding.
          What happened to RedHill Biopharma’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of RedHill Biopharma?
          Among the largest hedge funds holding RedHill Biopharma’s share is ARK Investment Management LLC. It holds RedHill Biopharma’s shares valued at N/A.
            ---

            Company Description

            RedHill Biopharma

            RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. It operates through two segments: Commercial Operations and Research & Development. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's U.S. subsidiary. The Research and Development segment includes all activities related to the research and development of therapeutic candidates and is being performed by the Company. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Galectin Therapeutics
            Aptose Biosciences
            Kala Pharmaceuticals
            Cellectar Biosciences
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis